CALLABLE MULTI DEFENDER VONTI - NOVO-NORDISK B/ELI LILLY & CO | Market Closed - Bid/Ask 11:20:00 2024-05-15 EDT | After market 11:15:00 | |||
| 106 USD | +0.28% |
|
106.8 | +0.80% |
| Current month | +0.47% | ||
| 3 months | -0.19% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Static data
| Product type | Reverse Convertibles |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| RMBUPV | |
| ISIN | CH1300254328 |
| Date issued | 2023-12-08 |
| Strike | 598 $ |
| Maturity | 2025-06-10 (385 Days) |
| Parity | 0.6 : 1 |
| Emission price | 100 $ |
| Emission volume | N/A |
| Settlement | both |
| Currency | USD |
Technical Indicators
| Highest since issue | 106.7 $ |
|---|---|
| Lowest since issue | 99.5 $ |
| Spread | 17 $ |
| Spread % | 1.58% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
783.2
USD
Average target price
850.4
USD
Spread / Average Target
+8.58%
- Stock Market
- Certificates
- RMBUPV Certificat
